These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 9096324)

  • 1. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
    Sipley JD; Alexander DS; Testa JE; Quigley JP
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
    Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
    Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
    Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM; Strickland S
    J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
    Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
    Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
    Behrendt N; List K; Andreasen PA; Danø K
    Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.
    Planus E; Barlovatz-Meimon G; Rogers RA; Bonavaud S; Ingber DE; Wang N
    J Cell Sci; 1997 May; 110 ( Pt 9)():1091-8. PubMed ID: 9175705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q; Shaltiel S
    BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface.
    Ragno P; Montuori N; Rossi G
    Eur J Biochem; 1995 Oct; 233(2):514-9. PubMed ID: 7588796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme.
    Petersen HH; Hansen M; Schousboe SL; Andreasen PA
    Eur J Biochem; 2001 Aug; 268(16):4430-9. PubMed ID: 11502203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
    Baker MS; Bleakley P; Woodrow GC; Doe WF
    Cancer Res; 1990 Aug; 50(15):4676-84. PubMed ID: 2114945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
    Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
    J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human/chicken urokinase chimeras demonstrate sequences outside the serine protease domain that dictate autoactivation.
    Aimes RT; Regazzoni K; Quigley JP
    Thromb Haemost; 2003 Feb; 89(2):382-92. PubMed ID: 12574820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.
    Lin Z; Jiang L; Yuan C; Jensen JK; Zhang X; Luo Z; Furie BC; Furie B; Andreasen PA; Huang M
    J Biol Chem; 2011 Mar; 286(9):7027-32. PubMed ID: 21199867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.